Specific adverse events: thromboembolic events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review
Intervention not reported
Participants with non‐serious adverse events: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with non‐serious adverse events: up to 3 months' (very low certainty).
1 finding from 1 review
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation
1 finding from 1 review
Direct postoperative serious, life‐threatening adverse events · patients with tracheostomy
Percutaneous techniques showed no clear difference in direct postoperative serious, life‐threatening adverse events compared with surgical techniques (low certainty).
1 finding from 1 review
Number of participants withdrawing due to adverse events (AE) · scalp psoriasis
Steroid probably leads to lower number of participants withdrawing due to adverse events (AE) compared with vitamin D (moderate certainty).
1 finding from 1 review
Number of participants withdrawing due to adverse events (AE) · scalp psoriasis
Steroid plus vitamin D showed no clear difference in number of participants withdrawing due to adverse events (AE) compared with steroid (moderate certainty).
1 finding from 1 review
Adverse events (AEs; adverse drug reaction): sinoatrial block · patients with myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): sinoatrial block compared with disopyramide (very low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Adverse events (during stem cell mobilisation and collection) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
Plerixafor showed no clear difference in adverse events (during stem cell mobilisation and collection) compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ co‐trimoxazole prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ co‐trimoxazole prophylaxis only (moderate certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether E1B‐deleted (dl1520) adenovirus changes adverse events considered non‐serious (number of participants) compared with percutaneous ethanol injection (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Treatment‐related adverse events Anxiety: GAD‐7 (Spitzer 2006) · children, adolescents or adults with CF
Summary of findings: psychological interventions showed no clear difference in treatment‐related adverse events Anxiety: GAD‐7 (Spitzer 2006) compared with usual care (low certainty).
1 finding from 1 review
Adverse events (postoperative delirium during hospitalisation) · adults with dementia following hip fracture surgery
Interdisciplinary enhanced rehabilitation (inpatient rehabilitation) may leads to lower adverse events (postoperative delirium during hospitalisation) compared with conventional rehabilitation (low certainty).
1 finding from 1 review
Adverse events (number of participants with any adverse event) · adult participants, irrespective of gender and type of non‐cardiac surgery, with mild or severe preoperative anaemia
rHuEPO with iron showed no clear difference in adverse events (number of participants with any adverse event) compared with control treatment with or without iron (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events that result in the discontinuation of treatment · adults and children with confirmed clinical and parasitological P vivax malaria
It is very uncertain whether the intervention changes adverse events that result in the discontinuation of treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events that result in the discontinuation of treatment · adults and children with confirmed clinical and parasitological P vivax malaria
It is very uncertain whether the intervention changes adverse events that result in the discontinuation of treatment (very low certainty).
1 finding from 1 review